1
|
Adaptive T-cell immunity controls senescence-prone MyD88- or CARD11-mutant B-cell lymphomas. Blood 2021; 137:2785-2799. [PMID: 33232972 DOI: 10.1182/blood.2020005244] [Citation(s) in RCA: 25] [Impact Index Per Article: 8.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/10/2020] [Accepted: 11/10/2020] [Indexed: 12/19/2022] Open
Abstract
Aberrant B-cell receptor/NF-κB signaling is a hallmark feature of B-cell non-Hodgkin lymphomas, especially in diffuse large B-cell lymphoma (DLBCL). Recurrent mutations in this cascade, for example, in CD79B, CARD11, or NFKBIZ, and also in the Toll-like receptor pathway transducer MyD88, all deregulate NF-κB, but their differential impact on lymphoma development and biology remains to be determined. Here, we functionally investigate primary mouse lymphomas that formed in recipient mice of Eµ-myc transgenic hematopoietic stem cells stably transduced with naturally occurring NF-κB mutants. Although most mutants supported Myc-driven lymphoma formation through repressed apoptosis, CARD11- or MyD88-mutant lymphoma cells selectively presented with a macrophage-activating secretion profile, which, in turn, strongly enforced transforming growth factor β (TGF-β)-mediated senescence in the lymphoma cell compartment. However, MyD88- or CARD11-mutant Eµ-myc lymphomas exhibited high-level expression of the immune-checkpoint mediator programmed cell death ligand 1 (PD-L1), thus preventing their efficient clearance by adaptive host immunity. Conversely, these mutant-specific dependencies were therapeutically exploitable by anti-programmed cell death 1 checkpoint blockade, leading to direct T-cell-mediated lysis of predominantly but not exclusively senescent lymphoma cells. Importantly, mouse-based mutant MyD88- and CARD11-derived signatures marked DLBCL subgroups exhibiting mirroring phenotypes with respect to the triad of senescence induction, macrophage attraction, and evasion of cytotoxic T-cell immunity. Complementing genomic subclassification approaches, our functional, cross-species investigation unveils pathogenic principles and therapeutic vulnerabilities applicable to and testable in human DLBCL subsets that may inform future personalized treatment strategies.
Collapse
|
2
|
Schleich K, Kase J, Dörr JR, Trescher S, Bhattacharya A, Yu Y, Wailes EM, Fan DNY, Lohneis P, Milanovic M, Lau A, Lenze D, Hummel M, Chapuy B, Leser U, Reimann M, Lee S, Schmitt CA. H3K9me3-mediated epigenetic regulation of senescence in mice predicts outcome of lymphoma patients. Nat Commun 2020; 11:3651. [PMID: 32686676 PMCID: PMC7371731 DOI: 10.1038/s41467-020-17467-z] [Citation(s) in RCA: 17] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/07/2019] [Accepted: 06/24/2020] [Indexed: 12/18/2022] Open
Abstract
Lesion-based targeting strategies underlie cancer precision medicine. However, biological principles - such as cellular senescence - remain difficult to implement in molecularly informed treatment decisions. Functional analyses in syngeneic mouse models and cross-species validation in patient datasets might uncover clinically relevant genetics of biological response programs. Here, we show that chemotherapy-exposed primary Eµ-myc transgenic lymphomas - with and without defined genetic lesions - recapitulate molecular signatures of patients with diffuse large B-cell lymphoma (DLBCL). Importantly, we interrogate the murine lymphoma capacity to senesce and its epigenetic control via the histone H3 lysine 9 (H3K9)-methyltransferase Suv(ar)39h1 and H3K9me3-active demethylases by loss- and gain-of-function genetics, and an unbiased clinical trial-like approach. A mouse-derived senescence-indicating gene signature, termed "SUVARness", as well as high-level H3K9me3 lymphoma expression, predict favorable DLBCL patient outcome. Our data support the use of functional genetics in transgenic mouse models to incorporate basic biology knowledge into cancer precision medicine in the clinic.
Collapse
Affiliation(s)
- Kolja Schleich
- Charité - University Medical Center, Department of Hematology, Oncology and Tumor Immunology, Virchow Campus, and Molekulares Krebsforschungszentrum, Augustenburger Platz 1, 13353, Berlin, Germany
| | - Julia Kase
- Charité - University Medical Center, Department of Hematology, Oncology and Tumor Immunology, Virchow Campus, and Molekulares Krebsforschungszentrum, Augustenburger Platz 1, 13353, Berlin, Germany
| | - Jan R Dörr
- Charité - University Medical Center, Department of Hematology, Oncology and Tumor Immunology, Virchow Campus, and Molekulares Krebsforschungszentrum, Augustenburger Platz 1, 13353, Berlin, Germany
| | - Saskia Trescher
- Institute for Computer Science, Humboldt-Universität zu Berlin, Unter Den Linden 6, 10099, Berlin, Germany
| | - Animesh Bhattacharya
- Charité - University Medical Center, Department of Hematology, Oncology and Tumor Immunology, Virchow Campus, and Molekulares Krebsforschungszentrum, Augustenburger Platz 1, 13353, Berlin, Germany
| | - Yong Yu
- Max-Delbrück-Center for Molecular Medicine in the Helmholtz Association, Robert-Rössle-Straße 10, 13125, Berlin, Germany
| | - Elizabeth M Wailes
- Charité - University Medical Center, Department of Hematology, Oncology and Tumor Immunology, Virchow Campus, and Molekulares Krebsforschungszentrum, Augustenburger Platz 1, 13353, Berlin, Germany
| | - Dorothy N Y Fan
- Charité - University Medical Center, Department of Hematology, Oncology and Tumor Immunology, Virchow Campus, and Molekulares Krebsforschungszentrum, Augustenburger Platz 1, 13353, Berlin, Germany.,Deutsches Konsortium für Translationale Krebsforschung (German Cancer Consortium), Partner Site Berlin, Berlin, Germany
| | - Philipp Lohneis
- University Hospital Cologne, Pathology, Kerpener Straße 62, 50937, Cologne, Germany
| | - Maja Milanovic
- Charité - University Medical Center, Department of Hematology, Oncology and Tumor Immunology, Virchow Campus, and Molekulares Krebsforschungszentrum, Augustenburger Platz 1, 13353, Berlin, Germany
| | - Andrea Lau
- Charité - University Medical Center, Department of Hematology, Oncology and Tumor Immunology, Virchow Campus, and Molekulares Krebsforschungszentrum, Augustenburger Platz 1, 13353, Berlin, Germany
| | - Dido Lenze
- Charité - University Medical Center, Pathology, Charitéplatz 1, 10117, Berlin, Germany
| | - Michael Hummel
- Deutsches Konsortium für Translationale Krebsforschung (German Cancer Consortium), Partner Site Berlin, Berlin, Germany.,Charité - University Medical Center, Pathology, Charitéplatz 1, 10117, Berlin, Germany
| | - Bjoern Chapuy
- University Medical Center Göttingen, Department of Hematology and Medical Oncology, Robert-Koch-Straße 40, 37075, Göttingen, Germany
| | - Ulf Leser
- Institute for Computer Science, Humboldt-Universität zu Berlin, Unter Den Linden 6, 10099, Berlin, Germany
| | - Maurice Reimann
- Charité - University Medical Center, Department of Hematology, Oncology and Tumor Immunology, Virchow Campus, and Molekulares Krebsforschungszentrum, Augustenburger Platz 1, 13353, Berlin, Germany
| | - Soyoung Lee
- Charité - University Medical Center, Department of Hematology, Oncology and Tumor Immunology, Virchow Campus, and Molekulares Krebsforschungszentrum, Augustenburger Platz 1, 13353, Berlin, Germany.,Max-Delbrück-Center for Molecular Medicine in the Helmholtz Association, Robert-Rössle-Straße 10, 13125, Berlin, Germany.,Deutsches Konsortium für Translationale Krebsforschung (German Cancer Consortium), Partner Site Berlin, Berlin, Germany
| | - Clemens A Schmitt
- Charité - University Medical Center, Department of Hematology, Oncology and Tumor Immunology, Virchow Campus, and Molekulares Krebsforschungszentrum, Augustenburger Platz 1, 13353, Berlin, Germany. .,Max-Delbrück-Center for Molecular Medicine in the Helmholtz Association, Robert-Rössle-Straße 10, 13125, Berlin, Germany. .,Deutsches Konsortium für Translationale Krebsforschung (German Cancer Consortium), Partner Site Berlin, Berlin, Germany. .,Kepler University Hospital, Department of Hematology and Oncology, Johannes Kepler University, Krankenhausstraße 9, 4020, Linz, Austria. .,Berlin Institute of Health, Anna-Louisa-Karsch-Straße 2, 10178, Berlin, Germany.
| |
Collapse
|
3
|
Gainey SJ, Horn GP, Towers AE, Oelschlager ML, Tir VL, Drnevich J, Fent KW, Kerber S, Smith DL, Freund GG. Exposure to a firefighting overhaul environment without respiratory protection increases immune dysregulation and lung disease risk. PLoS One 2018; 13:e0201830. [PMID: 30130361 PMCID: PMC6103500 DOI: 10.1371/journal.pone.0201830] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/08/2018] [Accepted: 07/23/2018] [Indexed: 01/29/2023] Open
Abstract
Firefighting activities appear to increase the risk of acute and chronic lung disease, including malignancy. While self-contained breathing apparatuses (SCBA) mitigate exposures to inhalable asphyxiates and carcinogens, firefighters frequently remove SCBA during overhaul when the firegrounds appear clear of visible smoke. Using a mouse model of overhaul without airway protection, the impact of fireground environment exposure on lung gene expression was assessed to identify transcripts potentially critical to firefighter-related chronic pulmonary illnesses. Lung tissue was collected 2 hrs post-overhaul and evaluated via whole genome transcriptomics by RNA-seq. Although gas metering showed that the fireground overhaul levels of carbon monoxide (CO), carbon dioxide (CO2), hydrogen cyanine (HCN), hydrogen sulfide (H2S) and oxygen (O2) were within NIOSH ceiling recommendations, 3852 lung genes were differentially expressed when mice exposed to overhaul were compared to mice on the fireground but outside the overhaul environment. Importantly, overhaul exposure was associated with an up/down-regulation of 86 genes with a fold change of 1.5 or greater (p<0.5) including the immunomodulatory-linked genes S100a8 and Tnfsf9 (downregulation) and the cancer-linked genes, Capn11 and Rorc (upregulation). Taken together these findings indicate that, without respiratory protection, exposure to the fireground overhaul environment is associated with transcriptional changes impacting proteins potentially related to inflammation-associated lung disease and cancer.
Collapse
Affiliation(s)
- Stephen J. Gainey
- Department of Animal Sciences, University of Illinois, Urbana, Illinois, United States of America
| | - Gavin P. Horn
- Illinois Fire Service Institute, Champaign, Illinois, United States of America
| | - Albert E. Towers
- Division of Nutritional Sciences, University of Illinois, Urbana, Illinois, United States of America
| | - Maci L. Oelschlager
- Department of Pathology, Program in Integrative Immunology and Behavior, University of Illinois College of Medicine, Urbana, Illinois, United States of America
| | - Vincent L. Tir
- Department of Pathology, Program in Integrative Immunology and Behavior, University of Illinois College of Medicine, Urbana, Illinois, United States of America
| | - Jenny Drnevich
- Roy J. Carver Biotechnology Center, University of Illinois, Urbana, Illinois, United States of America
| | - Kenneth W. Fent
- Division of Surveillance, Hazard Evaluations, and Field Studies, National Institute for Occupational Safety and Health, Cincinnati, Ohio, United States of America
| | - Stephen Kerber
- Director, UL Firefighter Safety Research Institute, Columbia, Maryland, United States of America
| | - Denise L. Smith
- Illinois Fire Service Institute, Champaign, Illinois, United States of America
- Department of Health and Human Physiological Sciences, Skidmore College, Saratoga Spring, New York, United States of America
| | - Gregory G. Freund
- Department of Animal Sciences, University of Illinois, Urbana, Illinois, United States of America
- Division of Nutritional Sciences, University of Illinois, Urbana, Illinois, United States of America
- Department of Pathology, Program in Integrative Immunology and Behavior, University of Illinois College of Medicine, Urbana, Illinois, United States of America
| |
Collapse
|
4
|
Franco F, González-Rincón J, Lavernia J, García JF, Martín P, Bellas C, Piris MA, Pedrosa L, Miramón J, Gómez-Codina J, Rodríguez-Abreu D, Machado I, Illueca C, Alfaro J, Provencio M, Sánchez-Beato M. Mutational profile of primary breast diffuse large B-cell lymphoma. Oncotarget 2017; 8:102888-102897. [PMID: 29262531 PMCID: PMC5732697 DOI: 10.18632/oncotarget.21986] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/09/2017] [Accepted: 10/03/2017] [Indexed: 01/09/2023] Open
Abstract
Primary breast lymphoma is a rare form of extra-nodal lymphoid neoplasm. The most common histological type is the diffuse large B-cell lymphoma, which represents 60–80% of all the cases. Our study analyzes the mutational profile of the primary lymphoma of the breast through targeted massive sequencing with a panel of 38 genes in a group of 17 patients with primary breast diffuse large B-cell lymphoma. Seventy-point-five percent of the patients presented with stage IE and 29.5% with stage IIE. 44% of the cases correspond to lymphomas with germinal center phenotype and 33.3% to activated B-cell. The genes with a higher mutational frequency include PIM1 (in 50% of the analyzed samples), MYD88 (39%), CD79B, PRDM1 and CARD11 (17%), KMT2D, TNFIAP3 and CREBBP (11%). The profile of mutant genes involves mostly the NFκB signaling pathway. The high frequency of mutations in PIM1 compared with other lymphomas may have implications in the clinical presentation and evolution of this type of lymphoma.
Collapse
Affiliation(s)
- Fernando Franco
- Medical Oncology Department, Hospital Universitario Puerta de Hierro, Madrid, Spain.,GOTEL (Spanish Lymphoma Oncology Group), Madrid, Spain
| | - Julia González-Rincón
- Group of Research in Lymphomas, Medical Oncology Department, Instituto de Investigación Sanitaria Puerta de Hierro-Segovia de Arana, Madrid, Spain.,Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain
| | - Javier Lavernia
- GOTEL (Spanish Lymphoma Oncology Group), Madrid, Spain.,Medical Oncology Department, Instituto Valenciano de Oncología, Valencia, Spain
| | - Juan F García
- Pathology Department, MD Anderson Cancer Center, Madrid, Spain
| | - Paloma Martín
- Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain.,Pathology Department, Hospital Universitario Puerta de Hierro, Madrid, Spain
| | - Carmen Bellas
- Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain.,Pathology Department, Hospital Universitario Puerta de Hierro, Madrid, Spain
| | - Miguel A Piris
- Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain.,Pathology Department, Hospital Universitario Fundación Jiménez Díaz, Madrid, Spain
| | - Lucia Pedrosa
- Group of Research in Lymphomas, Medical Oncology Department, Instituto de Investigación Sanitaria Puerta de Hierro-Segovia de Arana, Madrid, Spain
| | - José Miramón
- GOTEL (Spanish Lymphoma Oncology Group), Madrid, Spain.,Medical Oncology Department, Hospital Serranía de Ronda, Málaga, Spain
| | - José Gómez-Codina
- GOTEL (Spanish Lymphoma Oncology Group), Madrid, Spain.,Medical Oncology Department, Hospital Universitari i Politècnic La Fe, Valencia, Spain
| | - Delvys Rodríguez-Abreu
- GOTEL (Spanish Lymphoma Oncology Group), Madrid, Spain.,Medical Oncology Department, Hospital Universitario Insular de Gran Canaria, Las Palmas, Spain
| | - Isidro Machado
- Pathology Department, Instituto Valenciano de Oncología, Valencia, Spain
| | - Carmen Illueca
- Pathology Department, Instituto Valenciano de Oncología, Valencia, Spain
| | - Jesús Alfaro
- GOTEL (Spanish Lymphoma Oncology Group), Madrid, Spain.,Medical Oncology Department, Instituto Oncológico de Kutxa, Donostia, Spain
| | - Mariano Provencio
- Medical Oncology Department, Hospital Universitario Puerta de Hierro, Madrid, Spain.,GOTEL (Spanish Lymphoma Oncology Group), Madrid, Spain
| | - Margarita Sánchez-Beato
- GOTEL (Spanish Lymphoma Oncology Group), Madrid, Spain.,Group of Research in Lymphomas, Medical Oncology Department, Instituto de Investigación Sanitaria Puerta de Hierro-Segovia de Arana, Madrid, Spain
| |
Collapse
|
5
|
Takahara T, Matsuo K, Seto M, Nakamura S, Tsuzuki S. Synergistic activity of Card11 mutant and Bcl6 in the development of diffuse large B-cell lymphoma in a mouse model. Cancer Sci 2016; 107:1572-1580. [PMID: 27560392 PMCID: PMC5132338 DOI: 10.1111/cas.13057] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/16/2016] [Revised: 08/05/2016] [Accepted: 08/13/2016] [Indexed: 12/17/2022] Open
Abstract
Diffuse large B-cell lymphoma (DLBCL) is the most common subtype of malignant lymphoma; it derives from germinal center B cells. Although DLBCL harbors many genetic alterations, synergistic roles between such alterations in the development of lymphoma are largely undefined. We previously established a mouse model of lymphoma by transplanting gene-transduced germinal center B cells into mice. Here, we chose one of the frequently mutated genes in DLBCL, Card11 mutant, to explore its possible synergy with other genes, using our lymphoma model. Given that BCL6 and BCL2 expression and/or function are often deregulated in human lymphoma, we examined the possible synergy between Card11, Bcl6, and Bcl2. Germinal center B cells were induced in vitro, transduced with Card11 mutant, Bcl6, and Bcl2, and transplanted. Mice rapidly developed lymphomas, with exogenously transduced Bcl2 being dispensable. Although some mice developed lymphoma in the absence of transduced Bcl6, the absence was compensated by elevated expression of endogenous Bcl6. Additionally, the synergy between Card11 mutant and Bcl6 in the development of lymphoma was confirmed by the fact that the combination of Card11 mutant and Bcl6 caused lymphoma or death significantly earlier and with higher penetrance than Card11 mutant or Bcl6 alone. Lymphoma cells expressed interferon regulatory factor 4 and PR domain 1, indicating their differentiation toward plasmablasts, which characterize activated B cell-like DLBCL that represents a clinically aggressive subtype in humans. Thus, our mouse model provides a versatile tool for studying the synergistic roles of altered genes underlying lymphoma development.
Collapse
Affiliation(s)
- Taishi Takahara
- Division of Molecular Medicine, Aichi Cancer Center, Research Institute, Nagoya, Japan.,Department of Pathology and Clinical Laboratory, Nagoya University Hospital, Nagoya, Japan.,Department of Surgical Pathology, Aichi Medical University Hospital, Nagakute, Japan
| | - Keitaro Matsuo
- Division of Molecular Medicine, Aichi Cancer Center, Research Institute, Nagoya, Japan
| | - Masao Seto
- Department of Pathology, Kurume University School of Medicine, Kurume, Japan
| | - Shigeo Nakamura
- Department of Pathology and Clinical Laboratory, Nagoya University Hospital, Nagoya, Japan
| | - Shinobu Tsuzuki
- Division of Molecular Medicine, Aichi Cancer Center, Research Institute, Nagoya, Japan.,Department of Biochemistry, Aichi Medical University School of Medicine, Nagakute, Japan
| |
Collapse
|